Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
The British Journal of Dermatology
|
February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma
Georg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Characterisation and outcome of RAC1 mutated melanoma
Georg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas
Philipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
Anne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
Immunity
|
June 14, 2023
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses
Felix Bayerl, Philippa Meiser, Sainitin Donakonda, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
Carl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG
Sophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
Anne Zaremba, Manuel Philip, Jessica C Hassel, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
The British Journal of Dermatology
|
February 20, 2026
Melanoma of unknown primary shows oncogenic pattern and clinical course of sun-exposed melanoma
Georg Lodde, Jonida Dollani, Wolfgang Galetzka, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Characterisation and outcome of RAC1 mutated melanoma
Georg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 26, 2026
Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study
Lea Jessica Albrecht, Jana Garnier, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas
Philipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG
Anne Zaremba, Peter Mohr, Ralf Gutzmer, et al.
Immunity
|
June 14, 2023
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses
Felix Bayerl, Philippa Meiser, Sainitin Donakonda, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
Carl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 2, 2022
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG
Sophia Kreft, Valerie Glutsch, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2021
Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases
Anne Zaremba, Manuel Philip, Jessica C Hassel, et al.
Page
of 5